Scholarlink

Background <p>Different alternatives exist to prevent chemotherapy-induced alopecia (CIA), such as scalp cooling (SC). We conducted an economic evaluation to assess SC systems for breast cancer patients in Spain.</p> Methods <p>A decision tree was built to compare automated SC systems (DigniCap<sup>®</sup> and Paxman) with the usual clinical practice in Spain (not using the SC), over an 18-month time horizon and applying the National Health Service (NHS) and social perspectives. The target population were women diagnosed with breast cancer (stages I and II), undergoing chemotherapy treatment. We estimated the number of women preventing CIA, quality-adjusted life years (QALYs), incremental costs, and the incremental cost-effectiveness ratio (ICER). Deterministic and probabilistic sensitivity analyses were performed.</p> Results <p>The DigniCap<sup>®</sup> system increased costs by €505.97 and €251.8 (NHS and social perspectives), while the Paxman system did by €176.95 (NHS perspective), compared to not using SC. Both systems could generate 0.03 QALYs more than the usual clinical practice. The ICERs were below the willingness to pay threshold (€25 000 per QALY). Paxman, from the social perspective, represented a cost reduction of €77.22, being less costly and more effective in terms of QALYs. Sensitivity analyses confirmed these results. SC systems prevented CIA in 47% of the target population.</p> Conclusions <p>Automated SC systems could generate a higher cost (except Paxman from the social perspective) and more QALYs compared to the usual clinical practice in Spain. They could be considered cost-effectiveness technologies or a dominant alternative, in the case of Paxman applying a social perspective.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Economic evaluation of automated scalp cooling systems for breast cancer patients in Spain

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月17日

查看全文
  • Hernández-Yumar Aránzazu,
  • García-Pérez Lidia,
  • González-Pacheco Himar,
  • de Armas-Castellano Aythami,
  • Antón Torres Antonio,
  • Martín Jiménez Miguel,
  • Rueda-Domínguez Antonio,
  • Serrano-Aguilar Pedro,
  • Trujillo-Martín María del Mar

摘要

Background

Different alternatives exist to prevent chemotherapy-induced alopecia (CIA), such as scalp cooling (SC). We conducted an economic evaluation to assess SC systems for breast cancer patients in Spain.

Methods

A decision tree was built to compare automated SC systems (DigniCap® and Paxman) with the usual clinical practice in Spain (not using the SC), over an 18-month time horizon and applying the National Health Service (NHS) and social perspectives. The target population were women diagnosed with breast cancer (stages I and II), undergoing chemotherapy treatment. We estimated the number of women preventing CIA, quality-adjusted life years (QALYs), incremental costs, and the incremental cost-effectiveness ratio (ICER). Deterministic and probabilistic sensitivity analyses were performed.

Results

The DigniCap® system increased costs by €505.97 and €251.8 (NHS and social perspectives), while the Paxman system did by €176.95 (NHS perspective), compared to not using SC. Both systems could generate 0.03 QALYs more than the usual clinical practice. The ICERs were below the willingness to pay threshold (€25 000 per QALY). Paxman, from the social perspective, represented a cost reduction of €77.22, being less costly and more effective in terms of QALYs. Sensitivity analyses confirmed these results. SC systems prevented CIA in 47% of the target population.

Conclusions

Automated SC systems could generate a higher cost (except Paxman from the social perspective) and more QALYs compared to the usual clinical practice in Spain. They could be considered cost-effectiveness technologies or a dominant alternative, in the case of Paxman applying a social perspective.